Prognostic factors in patients with uterine sarcoma: the SARCUT study
Jazyk angličtina Země Velká Británie, Anglie Médium electronic
Typ dokumentu multicentrická studie, časopisecké články
PubMed
37192761
DOI
10.1136/ijgc-2022-004204
PII: ijgc-2022-004204
Knihovny.cz E-zdroje
- Klíčová slova
- sarcoma, uterine cancer,
- MeSH
- adenosarkom * terapie patologie MeSH
- endometriální stromální sarkom * terapie patologie MeSH
- leiomyosarkom * patologie MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- nádory dělohy * patologie MeSH
- nádory endometria * patologie MeSH
- nádory pánve * MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- sarkom * diagnóza MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
OBJECTIVE: Uterine sarcomas are a rare and heterogeneous group of malignancies that include different histological sub-types. The aim of this study was to identify and evaluate the impact of the different prognostic factors on overall survival and disease-free survival of patients with uterine sarcoma. METHODS: This international multicenter retrospective study included 683 patients diagnosed with uterine sarcoma at 46 different institutions between January 2001 and December 2007. RESULTS: The 5-year overall survival for leiomyosarcoma, endometrial stromal sarcoma, undifferentiated sarcoma, and adenosarcoma was 65.3%, 78.3%, 52.4%, and 89.5%, respectively, and the 5-year disease-free survival was 54.3%, 68.1%, 40.3%, and 85.3%, respectively. The 10-year overall survival for leiomyosarcoma, endometrial stromal sarcoma, undifferentiated sarcoma and adenosarcoma was 52.6%, 64.8%, 52.4%, and 79.5%, respectively, and the 10-year disease-free survival was 44.7%, 53.3%, 40.3%, and 77.5%, respectively. The most significant factor associated with overall survival in all types of sarcoma except for adenosarcoma was the presence of residual disease after primary treatment. In adenosarcoma, disease stage at diagnosis was the most important factor (hazard ratio 17.7; 95% CI 2.86 to 109.93). CONCLUSION: Incomplete cytoreduction, tumor persistence, advanced stage, extra-uterine and tumor margin involvement, and the presence of necrosis were relevant prognostic factors significantly affecting overall survival in uterine sarcoma. The presence of lymph vascular space involvement and administration of adjuvant chemotherapy were significantly associated with a higher risk of relapse.
Catalan Institute of Oncology L'Hospitalet de Llobregat Catalunya Spain
Department of Gynecology and Obstetrics Innsbruck Medical Univeristy Innsbruck Austria
Department of Obstetrics and Gynaecology Lithuanian University of Health Sciences Kaunas Lithuania
Gynecologic Oncology Department Clinica Diatros Barcelona Spain
Gynecologic Oncology Department Fondazione IRCCS Policlinico San Matteo Pavia Italy
Gynecologic Oncology Department Hospital Luis Tisné Universidad de Chile Santiago Chile
Gynecologic Oncology Department Hospital Universitario Miguel Servet Zaragoza Spain
Gynecologic Oncology Department Hospital Universitario Santa Cristina Madrid Spain
Gynecologic Oncology Department IRCCS Milan Italy
Gynecologic Oncology Department IRCCS Regina Elena National Cancer Institute Rome Italy
Gynecologic Oncology Department Metaxa Memorial Cancer Hospital Piraeus Greece
Gynecologic Oncology Department N N Alexandrov National Cancer Center Minsk Belarus
Gynecologic Oncology Department Tepecik Training and Research Hospital Clinics Konak Izmir Turkey
Gynecologic Oncology Department Torrecárdenas Hospital Complex Almeria Andalucía Spain
Gynecologic Oncology Unit Complejo Hospitalario de Navarra Pamplona Navarra Spain
Gynecologic Oncology Unit Hospital Clinico San Carlos Madrid Comunidad de Madrid Spain
Gynecologic Oncology Unit La Paz University Hospital Madrid Spain
Gynecological Oncology N N Alexandrov National Cancer Center Minsk Belarus
Obstetrics and Gynecology Clinica Universidad de Navarra Madrid Spain
Oncogynecology Grigoriev Institute for Medical Radiology NAMS of Ukraine Harkiv Ukraine
Oncology Radiology and Radiation Medicine 5 N Karazin Kharkiv National University Harkiv Ukraine
Riga East Clinical University Hospital Latvian Oncology Center Riga Latvia
Citace poskytuje Crossref.org